Loading organizations...
§ Private Profile · Dijon, Bourgogne, France
Clinical-stage biopharmaceutical company developing Live Biotherapeutics for immuno-oncology, infectious diseases, and immuno-inflammation.
Exeliom Biosciences is a clinical-stage biopharmaceutical company based in Paris and Dijon, France, that develops innovative live biotherapeutics based on microbiome immunomodulation. The enterprise leverages its deep knowledge of the microbiome-immunomodulation axis to create advanced next-generation immunotherapies targeting immuno-oncology, infectious diseases, and immuno-inflammation. Its lead therapeutic candidate, EXL01, utilizes the unique biological properties of the Faecalibacterium prausnitzii bacterium to treat severe medical conditions, specifically focusing on cancer and Clostridium difficile infections. Operating with a core team of two to ten employees, the firm recently completed an €8 million extension to reach €24 million in total Series A venture funding from recognizable lead investors like CE-Ventures to advance ongoing clinical trials. The company was founded in December 2016 by Chief Executive Officer Benjamin Hadida alongside Professor Harry Sokol, Doctor Philippe Langella, and Professor Patrick Gervais.
Exeliom has raised $20.5M across 3 funding rounds.
Exeliom has raised $20.5M in total across 3 funding rounds.
Exeliom has raised $20.5M in total across 3 funding rounds.
Exeliom's investors include Jean-Marie Lefevre, Crescent Ventures, Ismail Kola, UI Investissement, Crescent Enterprises, Auriga Partners, Biocodex, Capital Grand Est, INRA, Sofimac Innovation.
Exeliom has raised $20.5M across 3 funding rounds. Most recently, it raised $3.3M Series A Extension in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 21, 2025 | $3.3M Series A Plus | Jean Marie Lefevre | Crescent Ventures, Ismail Kola, UI Investissement | Announced |
| Jul 20, 2023 | $8.9M Series A Plus | Crescent Enterprises | Auriga Partners, Biocodex, Capital Grand EST, UI Investissement | Announced |
| Jul 9, 2018 | $8.2M Series A | Auriga Partners | Biocodex, Capital Grand EST, Inra, Sofimac Innovation | Announced |